The progressive nature of type 2 diabetes necessitates treatment intensification.
INTRODUCTION
Due to the progressive nature of type 2 diabetes, current therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), usually do not provide sustained glycemic control, so treatment intensification is necessary in many patients [1, 2] . Insulin remains the most efficacious glucose-lowering therapy, and is typically initiated when patients are unable to achieve glycemic control with lifestyle changes, oral antidiabetic drugs (OADs), and GLP-1RAs [2, 3] . GLP-1RAs can offer significant reductions in HbA 1c with a low risk of hypoglycemia and significant weight loss [4] . Several studies have demonstrated the clinical benefits of using basal insulin and GLP-1RAs together [5] [6] [7] [8] [9] , and their co-use is supported by treatment guidelines [2] . Thus, intensification with basal insulin is seen as a natural progression for patients whose blood glucose is not controlled by a GLP-1RA and OADs. Insulin degludec/liraglutide (IDegLira) is the first combination of a basal insulin (insulin degludec) and a GLP-1RA (liraglutide). The complementary modes of action of the two molecules can help to control both fasting plasma glucose (FPG) and postprandial glucose (PPG). IDegLira is available as a single once-daily injection that can be taken at any time of day, but preferably at the same time each day [10] . IDegLira is administered and titrated in a treat-to-target manner as dose steps, with each dose step containing 1 unit (U) of insulin degludec and 0.036 mg of liraglutide, up to a maximum of 50 dose steps (50 U insulin degludec and 1.8 mg liraglutide) daily [10] .
The DUAL phase 3 clinical trial program investigated the efficacy and safety of IDegLira in patients with type 2 diabetes. DUAL I and its 26-week extension showed that IDegLira provided clinical advantages and improved glycemic control compared with its monocomponents given alone in insulin-naïve patients [11, 12] . DUAL II investigated the contribution of liraglutide in IDegLira in insulin-experienced patients, with patients on IDegLira achieving superior glycemic control versus those on insulin degludec (which was capped at 50 U per day) [13] . DUAL IV investigated the efficacy and safety of IDegLira in insulin-naïve patients inadequately controlled with sulfonylurea with or without metformin, where it demonstrated superior glycemic control versus placebo [14] . DUAL V compared IDegLira with the uptitration of insulin glargine 100 units/mL in patients who were inadequately controlled on 20-50 U of insulin glargine 100 units/mL, with IDegLira resulting in superior HbA 1c , a lower rate of hypoglycemia, and weight loss versus insulin glargine 100 units/mL [15] .
The primary objective of the DUAL III clinical trial was to confirm the superiority of IDegLira compared with continuing on unchanged GLP-1RA therapy in controlling glycemia in insulin-naïve adult patients with type 2 diabetes who were inadequately controlled with the maximum approved or tolerated dose of a GLP-1RA and OADs. The secondary objective of the trial was to compare the general efficacy and safety of IDegLira with unchanged GLP-1RA.
METHODS

Trial Design and Participants
This was a 26-week, multi-center, randomized, open-label, two-group parallel, treat-to-target trial conducted at 81 sites in five countries (Australia, France, Hungary, Slovakia, and the United States) between August 2012 and March 2014. The trial was registered at clinicaltrials.gov (NCT01676116), and was conducted in accordance with Declaration of Helsinki and ICH Good Clinical Practice [16, 17] . Informed consent was obtained from all patients before they were included in the trial.
Insulin-naïve patients with type 2 diabetes were enrolled if they were inadequately controlled with a GLP-1RA and OADs (metformin alone or in combination with pioglitazone and/or sulfonylurea). Pre-trial patients were treated with the maximum dose (according to the local label) or the maximum tolerated dose of either liraglutide once daily or exenatide twice daily, and OADs at stable dose for at least 90 days before screening. Patients were included if they were C18 years of age, had an HbA 1c of 7.0-9.0% (53-75 mmol/mol, both inclusive), and a body mass index (BMI) B40 kg/ m 2 . Patients were excluded if they had used any OADs except for metformin, pioglitazone, and sulfonylurea within 90 days prior to screening. Full inclusion and exclusion criteria are provided in the Table S1 in the Electronic supplementary material, ESM.
Randomization and Masking
Patients were stratified according to pre-trial type of GLP-1RA and randomized 2:1 to IDegLira or to continue on unchanged GLP-1RA therapy using an interactive voice/ web response system. IDegLira was dosed once daily and could be administered at any time of the day, but preferably at the same time each day. Those on unchanged GLP-1RA continued on their pre-trial dosing regimen. Treatment assignment was masked for the safety committee and independent adjudication committee throughout the trial. No randomization codes were broken before database lock. Patients randomized to the unchanged GLP-1RA treatment continued their pre-trial treatment schedule without making any changes.
Procedures
Liraglutide (Victoza) was administered once daily using a 6.0 mg/mL solution provided in a 3-mL prefilled pen. Exenatide (Byetta) was administered twice daily using a 250 lg/mL solution provided in 1.2-mL or 2.4-mL prefilled pens. All previous OADs (metformin, pioglitazone, sulfonylurea) were continued at pre-trial doses in both groups unless there was a safety concern. OAD dose reduction was allowed for safety reasons (including hypoglycemic events) based on the judgment of the investigator.
At the screening visit, each patient was provided with a blood glucose monitoring meter in order to perform regular SMBG; this was used according to the manufacturer's instructions.
Outcomes
The primary endpoint was change in HbA 1c from baseline after 26 Patient-reported outcomes (PROs) were measured using the treatment-related impact measure-diabetes (TRIM-D) and diabetes treatment satisfaction questionnaire status (DTSQs) [18] [19] [20] . The TRIM-D questionnaire was used to measure the treatment-related impact of the diabetes medication, whereby a higher TRIM-D total score indicated a better health state [18, 19] . The DTSQs consisted of a questionnaire consisting of eight items; items 2 and 3 were perceived frequency of hyperglycemia and hypoglycemia, respectively, and were analyzed individually in the data analysis. A higher score for these items reflected a higher perceived frequency of hyperglycemia or hypoglycemia. The treatment satisfaction score was based on the sum of the remaining six items of the questionnaire. A higher score in the DTSQs treatment satisfaction scale total indicates higher patient satisfaction with treatment [20] .
Statistics
The trial was powered to the primary objective of demonstrating superiority using a two-sided t test of size 5%, under the assumptions of a 0.4% treatment difference with a 1.2% standard deviation. From these assumptions, a total of 429 patients were randomized 2:1 to IDegLira and unchanged GLP-1RA in order to obtain a nominal power of 90%.
The full analysis set (FAS) included all randomized subjects, and was used to analyze HbA 1c , FPG, SMBG, hypoglycemia, and body weight. The safety endpoints were summarized using the safety analysis set (SAS), which included all randomized subjects receiving at least one dose of the investigational product.
Missing values were imputed using last observation carried forward (LOCF). The primary endpoint was also analyzed for the per protocol analysis set (all subjects in the FAS who fulfilled the inclusion criteria, had not violated any of the exclusion criteria, had HbA 1c values from screening, randomization and after 12 weeks of treatment, and were exposed to the trial product for at least 12 weeks), completers analysis set (all randomized subjects who completed the trial), and using a repeated measurement analysis (missing data were imputed using a mixed-model repeated measurement technique rather than utilizing LOCF, in order to evaluate the sensitivity of using LOCF).
Change in HbA 1c was analyzed using an analysis of covariance (ANCOVA) on the FAS. Hypoglycemia was analyzed using a negative binomial regression model based on the FAS population, with treatment, pre-trial GLP-1RA, and region included as fixed factors and the logarithm of the time period in which an episode was considered treatment emergent as offset.
TRIM-D and DTSQs questionnaires were completed at baseline, visit 14, and the end of the trial. Change from baseline score in each subdomain as well as the total score after 26 weeks of treatment were analyzed for the FAS population by ANCOVA, with treatment, pre-trial GLP-1 RA, and region as fixed effects and baseline value as covariate.
RESULTS
Of the 704 patients screened, 438 were randomized to receive trial product; 292 to IDegLira and 146 to unchanged GLP-1RA ( Figure S1 in the ESM). Pre-trial, and in the unchanged GLP-1RA group, 79.5% of patients were treated with liraglutide and 20.5% with exenatide twice daily. A total of 94.5% of those randomized to IDegLira completed the trial versus 80.1% of those who were randomized to unchanged GLP-1RA. The baseline and demographic characteristics were similar for the treatment groups ( Fig. 1b) . 
DISCUSSION
Due to the progressive nature of type 2 diabetes, many patients need to intensify their treatment in order to maintain glycemic control. A commonly used approach is the initiation of a GLP-1RA after one or more OADs fail to keep a patient at the target HbA 1c [21] . There are currently several options for treatment intensification in patients on a GLP-1RA, and the addition of basal insulin is a recognized option in the ADA/EASD guidelines [2] .
Initiating basal insulin, and therefore the use of IDegLira, is a natural progression in the Overall, the safety and tolerability profile of IDegLira was consistent with previous findings [11] [12] [13] [14] . Initiation of IDegLira resulted in a statistically significantly increase in weight and a higher rate of hypoglycemia compared with unchanged GLP-1RA, however, this is to be expected following the introduction of insulin, and has been observed in other trials of insulin-naïve patients [22] [23] [24] [25] . Moreover, the rate of hypoglycemia was low in both groups.
The concomitant use of sulfonylurea in *23% of the patients in the IDegLira group may have also contributed to the hypoglycemia and weight gain. A post hoc summary showed that hypoglycemia was more frequent in the IDegLira plus sulfonylurea-treated patients versus those on IDegLira without sulfonylurea;
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